Table 3.
Cut off | Sensitivity (%) | Specificity (%) | PPV (%) | NPV (%) | LR+ | LR- | DOR | |
---|---|---|---|---|---|---|---|---|
T2 ratio | 1.9 | 69.8 | 80.0 | 83.3 | 64.9 | 3.5 | 0.4 | 8.8 |
EGEr | 3.8 | 72.1 | 50.0 | 67.4 | 55.6 | 1.4 | 0.6 | 2.3 |
LGE | – | 76.7 | 70.0 | 78.6 | 67.7 | 2.6 | 0.3 | 8.7 |
Native T1 (ms) | 1,228 | 86.0 | 93.3 | 94.9 | 82.4 | 12.8 | 0.2 | 64.0 |
ECV (%) | 31.0 | 65.1 | 83.3 | 84.8 | 62.5 | 3.9 | 0.4 | 9.8 |
T2 (ms) | 58.5 | 83.7 | 93.3 | 94.7 | 80.0 | 12.5 | 0.2 | 62.5 |
2009LLC | – | 79.1 | 73.3 | 80.9 | 71.0 | 3.0 | 0.3 | 10.0 |
2018LLC | – | 95.3 | 86.7 | 91.1 | 92.9 | 7.2 | 0.1 | 72.0 |
EGE, early gadolinium enhancement ratio; LGE, late gadolinium enhancement; ECV, extracellular volume fraction; LLC, Lake Louise criteria; PPV, positive predictive value; NPV, negative predictive value; LR+, positive likelihood ratio; LR-, negative likelihood ratio; DOR, diagnostic odds ratio.